

# The Association of Renin-Angiotensin System Blockades and Mortality in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease and Acute Respiratory Failure: A Retrospective Cohort Study

Zhishen Ruan<sup>1,\*</sup>, Dan Li<sup>1,\*</sup>, Yuanlong Hu<sup>1</sup>, Zhanjun Qiu<sup>1,2</sup>, Xianhai Chen<sup>1,2</sup>

<sup>1</sup>The First Clinical College, Shandong Chinese Medical University, Ji Nan, People's Republic of China; <sup>2</sup>Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji Nan, People's Republic of China

\*These authors contributed equally to this work

Correspondence: Zhanjun Qiu; Xianhai Chen, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Ji Nan, People's Republic of China, Tel/Fax +86 0531 18660199889, Email qiu zhj227@163.com; chenxianhai18@163.com

**Background:** Acute respiratory failure (ARF) is a common cause of admission to the intensive care unit (ICU) for patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). There is still a lack of effective interventions and treatments. ACE inhibitors (ACEI)/ angiotensin II receptor blockers (ARB) were effective in COPD patients. We aimed to study the effect of ACEI/ARB use on AECOPD combined with ARF and evaluate the effect of in-hospital continuation of medication.

**Methods:** We included patients with AECOPD and ARF from the Medical Information Bank for Intensive Care (MIMIC-III) database. MIMIC III is a large cohort database from Boston, USA. Patients were divided into two groups according to the use of ACEI/ARB before admission. Propensity score matching (PSM) was used to reduce potential bias between the two groups. Cox regression and Kaplan-Meier curves compared 30-day mortality in ACEI/ARB users and non-users. We also defined and analyzed the use of in-hospital ACEI/ARB. Multiple models were used to ensure the robustness of the findings. Subgroup analysis was used to analyze the variability between groups.

**Results:** A total of 544 patients were included in the original study. After PSM, 256 patients were included in the matched cohort. Multivariate Cox regression showed 30-day mortality was significantly lower in ACEI/ARB users compared with controls (HR = 0.50, 95% CI: 0.29–0.86,  $p = 0.013$ ). In PSM and inverse probability-weighted models, the results are stable Continued in-hospital use of ACEI/ARB remains effective (HR 0.40, 95% CI 0.22–0.74,  $p = 0.003$ ). Kaplan-Meier showed a significant difference in survival between the two groups.

**Conclusion:** This study found that pre-hospital ACEI/ARB use was associated with reduced mortality in patients with AECOPD and ARF.

**Keywords:** chronic obstructive pulmonary disease, acute respiratory failure, angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, mortality

## Background

In the intensive care unit (ICU), acute respiratory failure (ARF) is one of the most frequent complications in patients with acute exacerbations chronic obstructive pulmonary disease (AECOPD).<sup>1,2</sup> Effective treatment options remain limited, and it is necessary to explore appropriate methods to anti-inflammatory and protect against acute lung injury.

Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor antagonists (ARB), an inhibitor of the renin-angiotensin-aldosterone system, have been widely used in cardiovascular diseases. Previous studies have shown

a protective effect of ACEI/ARB in the prognosis of patients with COPD. Mancini reported that the use of ACEI/ARB reduced morbidity and mortality in COPD patients, suggesting its potential dual cardioprotective properties.<sup>3</sup> Subsequently, Mortensen found that patients with AECOPD using ACEI/ARB were associated with lower mortality.<sup>4</sup> There is a lack of studies on ACEI/ARB use in COPD combined with ARF patients admitted to the ICU, and it is unclear whether these patients should continue with ACEI/ARB. We hypothesized that ACEI/ARB would benefit patients with AECOPD and ARF. Hence, we decided to conduct a retrospective study to ascertain the association between ACEI/ARB use and mortality in these patients.

## Methods

### Study Design and Data Source

This study used a retrospective cohort study. Data were extracted from the Medical Information Bank for Intensive Care (MIMIC)-III (v 1.4). MIMIC-III covered 53423 adult patients hospitalized at the Beth Israel Deaconess Medical Center in Boston from June 2001 to October 2012.<sup>5</sup> One author Zhishen Ruan gained access to the database by completing the online course and passing the National Institutes of “Protecting Human Research Participants Exam” (certification number 43453324). The Institutional Review Board of Beth Israel Deaconess Medical Center and MIT affiliates approved the database.<sup>6</sup> Our findings were reported following the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.<sup>7</sup>

### Inclusion and Exclusion Criteria

We extracted patients with AECOPD and ARF diagnoses from MIMIC III based on SQL language. The diagnostic criteria were derived from the International Classification of Diseases, Ninth Revision. Unfortunately, the lung function test was lacking in the database to confirm COPD diagnosis. We considered patients with COPD and AECOPD diagnoses in the ICD-9 codes to reduce diagnostic errors as AECOPD patients. Patients with missing vital information, comorbid asthma, or admission time less than 24 hours were excluded from our cohort.

### Diagnostic Criteria and Drug Use

Primary diagnosis of COPD consistent with (ICD-9-CM codes: 490.x, 491.xx, 492.xx and 496.xx); secondary AECOPD diagnosis (ICD-9-CM codes: 491.21, 491.22); primary diagnosis of acute respiratory failure (ICD-9-CM codes: 518.81, 518.82, 518.84 or 799.1).<sup>8</sup> The diagnosis of other diseases is shown in [Table S1](#). The ACEI/ARB use was defined as a record of using ACEI or ARB in “Medications on admission” in MIMIC-III.<sup>4</sup> Medications classified as ACEIs were benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, and ramipril, and ARBs included candesartan, irbesartan, losartan, telmisartan and valsartan.<sup>9</sup> We included ARB in the ACEI category for the analysis in this study due to the small number of subjects using this class of medications. Other medications are also taken from “Medications on admission”. The specific drugs are presented in [Table S2](#).

### Demographic Characteristics

We extracted the following outcome variables: age, gender, ethnicity, smoking history, comorbidities (diabetes, hypertension, hyperlipidemia, coronary artery disease, congestive heart failure, stroke, pulmonary circulatory disease, peripheral vascular disease, pneumonia, sepsis, renal failure, cancer), mechanical ventilation, Acute Physiology Score III (APS III), quick sequential organ failure assessment score (qSOFA), acute physiology II (SAPSII), Oxford acute severity of illness score (OASIS), respiratory medication use (LABA: Long-acting  $\beta_2$  agonists, LAMA: long-acting muscarinic antagonist, inhaled and oral corticosteroid), Cardiovascular and other medications use (beta-blockers, calcium-channel blockers, diuretics, antiplatelet, nitrates, Anti-glycemic drugs, statins), arterial blood gases results, and length of hospital stay.

### Primary Outcome

Our primary outcome, 30-day mortality, was evaluated against a database developed and maintained by the MIT Computational Physiology Laboratory.<sup>5</sup>

## Statistical Analysis

We used propensity score matching (PSM) based on the 40 covariates described above to minimize potential bias in the treatment of allocation and confounding factors.<sup>10</sup> Variable matching follows a 1:1 nearest neighbor matching algorithm with a caliper width of 0.02. To assess the validity of the PSM, we compared the balance of covariates between the original and matched cohorts using standardized mean differences (SMD). SMD<0.1 is considered an acceptable result.<sup>9</sup>

Data were described as mean  $\pm$  standard deviation, median (25th–75th percentile), or number (percentage), depending on the type and distribution of the variable. Kruskal Wallis and Chi-square (or Fisher's exact) tests were used to compare among the categorical covariates. Cox proportional risk models were used to calculate the risk ratios (HRs) and 95% ci of patients applying ACEI/ARB with 30-day mortality levels. The cumulative rates of death were compared over 30-day using the Kaplan-Meier curves. To further analyze the impact of in-hospital ACEI/ARB use, we defined ACEI/ARB use records within 24 hours of the first admission as in-hospital ACEI/ARB use. We divided them into four groups for analysis based on pre-hospital and in-hospital use of ACEI/ARB.

We performed a series of sensitivity analyses to verify the robustness of the results. A Cox regression was then performed on the weighted cohort to obtain the results. Three association inference models were used: an inverse probability weighting model, a propensity score-based patient-matching model, and a Cox regression-based multi-variate analysis model. Cox proportional hazards regression was performed to adjust for the population before and after the propensity score. In addition, sensitivity analysis was used to analyze the differences between the subgroups.

The analyses were performed with the statistical software packages R v3.3.2 (<http://www.R-project.org>, The R Foundation) and Free Statistics software versions (1.4).

## Results

### Flow Chart

A total of 646 patients with AECOPD combined with ARF were extracted from the MIMIC-III. After excluding patients diagnosed with asthma and those hospitalized for less than 24 hours, 544 patients were included in the original cohort. (Figure 1)

### Characters of Patients


Population baseline information for all patients was presented in Table 1. 199 (36.6%) patients used ACEI/ARB in the original cohort. Patients in the ACEI/ARB group had more comorbidities: diabetes 74 (37.2) vs 76 (22.0), hypertension 35 (17.6) vs 31(9.0), CAD 62 (31.2) vs 64 (18.6). We used PSM to balance the variation between the two groups to reduce this potential bias. After PSM, 256 patients were included in the matched cohort. The mean ages of these patients were  $71.7 \pm 11.9$ , females accounted for 45.7%, 198 (77.3%) were whites, and 58 (22.7%) were non-whites.

### Clinical Outcomes

Multivariate Cox regression (Table 2) shows a protective effect of ACEI/ARB use on 30-day death in patients with AECOPD combined with ARF (HR = 0.51, 95% CI = 0.32–0.81,  $p = 0.005$ ). Compared to the group not in and pre-hospital ACEI/ARB use, the HRs of the other three groups were (in-hospital use: HR 0.51, 95% CI 0.24–1.07,  $p = 0.073$ ; pre-hospital use: HR 0.45, 95% 0.21–0.96,  $p = 0.039$ ; in and pre-hospital use: HR 0.40, 95% CI 0.22–0.74,  $p = 0.003$ ). K-M survival curves (Figure 2) revealed that the ACEI/ARB group had higher survival times and significantly lower mortality rates than patients in non-ACEI/ARB group. ( $p < 0.001$ ).

### Sensitivity Analysis

In the original cohort (N = 544), ACEI/ARB users remained protective for 30-day mortality in the model I (HR 0.50, 95% CI 0.29–0.86,  $p = 0.013$ ) after adjusting for various covariates, such as age, sex, comorbidities, pre-hospital medication, Severity scale, and ABG values. After PSM, the HR in model II (HR 0.56, 95% CI 0.34–0.94,  $p = 0.028$ ) and model III (HR 0.55, 95% CI 0.34–0.89,  $p = 0.014$ ) were similar to those before adjustment (Table 3). Table 4 shows the



**Figure I** The flow chart of study.

results of the subgroup analysis. [Table S3](#) is the subgroup analysis of in-hospital and pre-hospital use of ACEI/ARB. The HRs assessed by baseline risk factors were less than 1.0 for all subgroups.

## Discussion

In this study, ACEI/ARB pre-hospital users with AECOPD and ARF had lower 30-day mortality than non-ACEI/ARB users. This association is reliable in three models after PSM. Bidulka found that discontinuation of ACEI/ARB increased mortality in patients with kidney injury.<sup>11</sup> We further analyzed the prognosis of in-hospital use of ACEI/ARB in patients with AECOPD. Our results found that continued in-hospital use of ACEI/ARB was associated with lower mortality in patients with AECOPD and ARF.

In our study, 36.6% (199/544) of patients received ACEI or ARB, which was higher than the results of previous studies. Mortensen said that 32.0% of patients with AECOPD on ACEI/ARB and Tejawani in the COPD gene cohort study reported 28.0% of COPD patients using ACEI/ARB.<sup>4,12</sup> The higher rate of medication use may be related to the higher number of cardiovascular comorbidities in critically ill patients. In addition, the definition of ACEI/ARB use may have led to this discrepancy. ACEI/ARB exposure was a recent history of ACEI/ARB use in mimic-III. In contrast, Mortensen and Tejawani, in their cohorts, described ACEI/ARB exposure as ACEI/ARB use in the 90 days before hospital admission or continued ACEI/ARB use.

**Table I** Baseline Characteristics of Participants

Variables	Original Cohort			SMD	Matched Cohort			SMD
	All Patients (n= 544)	No ACEI/ARB (n=345)	ACEI/ARB (n=199)		All Patients (n= 256)	No ACEI/ARB (n=128)	ACEI/ARB (n=128)	
Sex, Female	258 (47.4)	162 (47.0)	96 (48.2)	0.03	117 (45.7)	58 (45.3)	59 (46.1)	0.02
Age, y	71.0 ± 11.6	70.3 ± 11.7	72.0 ± 11.3	0.15	71.7 ± 11.9	71.9 ± 12.0	71.4 ± 11.8	0.04
Ethnicity, white	410 (75.4)	258 (74.8)	152 (76.4)	0.04	198 (77.3)	99 (77.3)	99 (77.3)	<0.001
Smoker	438 (80.5)	288 (83.5)	150 (75.4)	0.20	197 (77.0)	101 (78.9)	96 (75.0)	0.09
<b>Comorbidities</b>								
Diabetes	150 (27.6)	76 (22.0)	74 (37.2)	0.34	86 (33.6)	44 (34.4)	42 (32.8)	0.03
Hypertension	66 (12.1)	31 (9.0)	35 (17.6)	0.26	37 (14.5)	21 (16.4)	16 (12.5)	0.11
Hyperlipidemia	141 (25.9)	74 (21.4)	67 (33.7)	0.28	76 (29.7)	37 (28.9)	39 (30.5)	0.03
CAD	126 (23.2)	64 (18.6)	62 (31.2)	0.30	73 (28.5)	36 (28.1)	37 (28.9)	0.02
CHF	217 (39.9)	134 (38.8)	83 (41.7)	0.06	106 (41.4)	53 (41.4)	53 (41.4)	<0.001
Stroke	26 (4.8)	18 (5.2)	8 (4.0)	0.06	11 (4.3)	5 (3.9)	6 (4.7)	0.04
PC	44 (8.1)	23 (6.7)	21 (10.6)	0.14	22 (8.6)	13 (10.2)	9 (7.0)	0.11
PVD	53 (9.7)	29 (8.4)	24 (12.1)	0.12	21 (8.2)	11 (8.6)	10 (7.8)	0.03
Pneumonia	334 (61.4)	205 (59.4)	129 (64.8)	0.11	158 (61.7)	78 (60.9)	80 (62.5)	0.03
Sepsis	91 (16.7)	58 (16.8)	33 (16.6)	0.01	46 (18.0)	24 (18.8)	22 (17.2)	0.04
Renal failure	83 (15.3)	45 (13.0)	38 (19.1)	0.17	39 (15.2)	22 (17.2)	17 (13.3)	0.11
Cancer	62 (10.1)	29 (8.4)	12 (6.0)	0.09	18 (7.0)	9 (7.0)	9 (7.0)	<0.001
Mechanical ventilation	420 (68.1)	217 (62.9)	123 (61.8)	0.02	158 (61.7)	80 (62.5)	78 (60.9)	0.03
<b>Severity scales</b>								
APSI	44.6 ± 17.4	44.8 ± 17.5	44.1 ± 17.2	0.04	44.5 ± 17.7	44.5 ± 17.2	44.5 ± 18.3	0.01
qSOFA	1.7 ± 0.8	1.7±0.8	1.7 ±0.7	0.08	1.7 ± 0.8	1.7±0.9	1.7±0.7	0.03
SAPSI	38.0 ± 12.6	38.0 ± 13.2	38.0 ± 11.5	0.01	37.6 ± 13.0	37.4 ± 13.7	37.8 ± 12.3	0.03
OASIS	35.0 ± 9.2	35.5 ± 9.1	34.0 ± 9.3	0.16	34.8 ± 9.6	35.0 ± 9.8	34.6 ± 9.3	0.04
<b>Respiratory medications use</b>								
LABA	166 (30.5)	107 (31.0)	59 (29.6)	0.03	81 (31.6)	43 (33.6)	38 (29.7)	0.08
LAMA	122 (22.4)	75 (21.7)	47 (23.6)	0.05	63 (24.6)	31 (24.2)	32 (25.0)	0.02
Inhaled corticosteroid	230 (42.3)	155 (44.9)	75 (37.7)	0.15	99 (38.7)	53 (41.4)	46 (35.9)	0.11
Oral corticosteroid	144 (26.5)	106 (30.7)	38 (19.1)	0.27	62 (24.2)	29 (22.7)	33 (25.8)	0.07
<b>Cardiovascular and other medications</b>								
Beta-blockers	180 (33.1)	103 (29.9)	77 (38.7)	0.19	117 (40.9)	46 (35.9)	43 (33.6)	0.05
Calcium-channel blocker	136 (25.0)	80 (23.2)	56 (28.1)	0.11	64 (22.4)	35 (27.3)	33 (25.8)	0.04
Diuretics	53 (9.7)	111 (32.2)	87 (43.7)	0.24	120 (42.0)	60 (46.9)	53 (41.4)	0.11
Antiplatelet	235 (38.1)	113 (32.8)	95 (47.7)	0.31	123 (43.0)	56 (43.8)	60 (46.9)	0.06
Nitrates	55 (8.9)	24 (7.0)	29 (14.6)	0.25	28 (9.8)	17 (13.3)	18 (14.1)	0.02
Anti-glycemic drugs	57 (10.5)	23 (6.7)	34 (17.1)	0.33	30 (10.5)	15 (11.7)	16 (12.5)	0.02
Statins	196 (36.0)	90 (26.1)	106 (53.3)	0.58	104 (40.6)	51 (39.8)	53 (41.4)	0.03
<b>ABG values on the admission</b>								
PaCO <sub>2</sub>	56.0 ± 17.6	56.0 ± 17.8	55.9 ± 17.5	0.01	56.2 ± 17.8	57.1 ± 19.3	55.3 ± 16.2	0.10
PH	7.32±0.11	7.35 (0.09)	7.34 (0.08)	0.09	7.34 ± 0.08	7.34 ±0.09	7.35±0.07	0.01
PaO <sub>2</sub> /FiO <sub>2</sub>	212 (130, 251)	214 (130, 255)	207 (133, 239)	0.09	217 (137, 255)	217 (141, 251)	215 (133, 257)	0.02
Time in hospital	11.6 ± 9.1	11.3±9.1	12.2 ±9.1	0.09	11.6 ± 9.5	11.9±9.7	11.6±8.9	0.04
Time in ICU	6.4 ± 7.1	6.0±6.8	7.1±7.6	0.16	7.6 ± 8.9	7.0±8.8	6.4±6.4	0.08

**Abbreviations:** CAD, Coronary artery disease; CHF, Congestive heart failure; PC, Pulmonary circulation disease; PVD, Peripheral vascular disease; APS III, Acute Physiology Score III; qSOFA, quick sequential organ failure assessment score; SAPSI, acute physiology II; OASIS, Oxford acute severity of illness score; LABA, Long-acting  $\beta_2$  agonists; LAMA, long-acting muscarinic antagonist; SMD, standardized mean difference.

As far back as 2006, Mancini identified a protective effect of ACEI/ARB use in COPD.<sup>3</sup> After that, Mortensen placed this effect and found that patients  $\geq 65$  years with AECOPD treated with ACE inhibitors were associated with lower 90-day all-cause mortality (OR 0.55, 95% CI 0.45–0.66).<sup>4</sup> However, they only studied older male patients, which

**Table 2** Univariate and Multivariate Cox Hazard Analysis of Risk Factors for 30-Day Mortality in AECOPD and ARF


Variables	Univariate Analysis		Multivariate Analysis	
	HR (95% CI)	P	HR (95% CI)	P
Sex, Female	1.46 (0.97–2.19)	0.068		
Age, y	1.06 (1.04–1.08)	<0.001	1.06 (1.02–1.09)	0.001
Ethnicity, white	1.34 (0.81–2.21)	0.255		
Smoker	1.22 (0.71–2.09)	0.466		
<b>Medications</b>				
ACEI/ARB	0.50 (0.32–0.81)	0.004	0.50 (0.29,0.86)	0.013
No ACEI/ARB use	1 (ref)		1 (ref)	
In-hospital ACEI/ARB use	0.53 (0.26–1.06)	0.074	0.51 (0.24–1.07)	0.073
Pre-hospital ACEI/ARB use	0.48 (0.27–0.85)	0.011	0.45 (0.21–0.96)	0.039
In and pre-hospital use	0.41 (0.20–0.86)	0.018	0.40 (0.22–0.74)	0.003
<b>Comorbidities</b>				
Diabetes	0.91 (0.58–1.44)	0.683		
Hypertension	1.06 (0.58–1.94)	0.846		
CAD	0.69 (0.41–1.16)	0.162		
CHF	1.7 (1.14–2.54)	0.01		
Stroke	1.16 (0.47–2.85)	0.749		
PC	1.07 (0.52–2.21)	0.855		
PVD	1.11 (0.57–2.13)	0.761		
Pneumonia	0.98 (0.65–1.48)	0.927		
Sepsis	2.38 (1.54–3.68)	<0.001	1.97 (1.11–3.47)	0.02
Renal failure	1.45 (0.88–2.4)	0.145		
Cancer	2.59 (1.49–4.49)	0.001	3.7 (1.78–7.68)	<0.001
Mechanical ventilation	0.99 (0.65–1.5)	0.963		

**Abbreviations:** LABA, Long-acting  $\beta_2$  agonists; LAMA, long-acting muscarinic antagonist; CAD, Coronary artery disease; CHF, Congestive heart failure; PC, Pulmonary circulation disease; PVD, Peripheral vascular disease.

may lead to potential bias. Our cohort focused on patients with AECOPD combined with ARF, adjusting for various confounding factors such as age, gender, comorbidities, arterial blood gas analysis, and preadmission medications. Thus, our study provides further evidence that ACEI/ARB use is associated with lower mortality in patients with AECOPD and ARF.

Over the past few years, there has been a proliferation of studies on ACEI/ARB and COPD. In COPD combined with pneumonia, Kim found that ACEI/ARB use reduced the incidence of pneumonia in COPD patients.<sup>13</sup> To differentiate the effect of ACEI and ARB, Lai conducted a study founding that ARB use was superior to the use of ACEI in COPD patients regarding the incidence of pneumonia and mortality.<sup>14</sup> Recently, several studies have found a potential therapeutic benefit of ACEI/ARB use in stable COPD patients. It plays a vital role in delaying the progression of emphysema and decline in lung function, improving lung compliance, decreasing peak response to exercise training, improving exercise capacity, and enhancing pulmonary rehabilitation.<sup>12,15–18</sup> These studies responded that ACEI/ARB could reduce the rate of lung function deterioration in COPD patients and reduce the risk of pneumonia, thereby reducing mortality in AECOPD combined with ARF.

Renin-Angiotensin System blockages are effective in acute respiratory distress syndrome (ARDS). Kim found that ARDS patients' mortality from ACEI/ARB during ICU admission was lower than no-ACEI/ARB users.<sup>19</sup> However, there was some bias in selecting medication use at entrance, with patients who survived longer being more opportunistic to take ACEI/ARB. Thus, for patients with acute viral respiratory illness (AVRI), Jeffery found a reduced probability of ARDS in AVRI patients on outpatient ARB and reduced 30-day mortality in patients on ACEI.<sup>20</sup>



**Figure 2** Kaplan-Meier survival curves for 30-day of AECOPD patients with ARF.

We can propose several explanations to analyze the association between ACEi/ARB use and lower mortality in patients with AECOPD combined with ARF.

First, the angiotensin-converting enzyme (ACE) is highly abundant in the lungs. When AECOPD combined with ARF occurs, acute alveolar hypoxia activates ACE, increasing the production of angiotensin II (Ang II).<sup>21,22</sup> In addition

**Table 3** Associations Between ACE Inhibitors Use and the 30-Day Mortality

	30-Day Mortality (%)	
<b>Original cohort</b>		
No ACE inhibitors	72/345 (20.86)	
ACE inhibitors	23/199 (11.55)	
<b>Matched cohort</b>		
No ACE inhibitors	29/128 (22.66)	
ACE inhibitors	12/128 (9.38)	
<b>30-day mortality</b>	<b>HR (95% CI)</b>	<b>P value</b>
Crude analysis	0.51 (0.32,0.81)	0.005
Multivariable analysis <sup>a</sup>	0.50 (0.29,0.86)	0.013
Adjusted for propensity score <sup>b</sup>	0.56 (0.34,0.94)	0.028
With inverse probability weighting <sup>c</sup>	0.55 (0.34,0.89)	0.014

**Notes:** <sup>a</sup>Shown is a multivariable Cox regression model of 544 patients by adjusting all covariates in Table 1.

<sup>b</sup>Shown is a multivariable Cox regression model adjusted for all covariates after propensity score matching.

<sup>c</sup>Shown is a multivariable Cox regression model adjusted for inverse probability-weighted covariates after propensity score matching.



**Table 4** Subgroup Analysis Between ACE Inhibitors Use and the 30-Day Mortality

Subgroup	No. Event_%	HR 95% CI	P	P for Interaction
<b>Age</b>				0.384
< 70	5/76 (6.6)	0.66 (0.24–1.80)	0.416	
≥70	18/123 (14.6)	0.39 (0.23–0.67)	0.001	
<b>Gender</b>				0.390
Female	8/103 (7.8)	0.34 (0.16–0.74)	0.007	
Male	15/96 (15.6)	0.51 (0.28–0.93)	0.029	
<b>Sepsis</b>				0.944
No	16/159 (10.1)	0.44 (0.25–0.78)	0.004	
Yes	7/40 (17.5)	0.47 (0.2–1.11)	0.085	
<b>Pneumonia</b>				0.643
No	9/70 (12.9)	0.5 (0.24–1.07)	0.075	
Yes	14/129 (10.9)	0.42 (0.23–0.77)	0.005	
<b>CAD</b>				0.134
No	20/137 (14.6)	0.54 (0.33–0.90)	0.019	
Yes	3/62 (4.8)	0.21 (0.06–0.73)	0.014	
<b>CHF</b>				0.218
No	13/116 (11.2)	0.57 (0.30–1.09)	0.092	
Yes	10/83 (12.0)	0.32 (0.16–0.65)	0.001	
<b>Renal failure</b>				0.578
No	17/161 (10.6)	0.40 (0.22–0.72)	0.002	
Yes	6/38 (15.8)	0.08 (0.01–0.92)	0.043	
<b>Hypertension</b>				0.705
No	18/164 (11.0)	0.43 (0.26–0.73)	0.002	
Yes	5/35 (14.3)	0.58 (0.17–1.95)	0.380	
<b>Diabetes</b>				0.449
No	17/125 (13.6)	0.50 (0.29–0.88)	0.016	
Yes	6/74 (8.1)	0.33 (0.13–0.84)	0.019	

**Abbreviations:** CAD, Coronary artery disease; CHF, Congestive heart failure.

to being a potent vasoconstrictor, Ang II appears to be an essential mediator of lung injury and apoptosis. It can modulate the inflammatory response by interfering with cytokine production, inflammatory cell migration, epithelial apoptosis, oxidative stress, activation of tissue mast cells, and lung fibrosis.<sup>23–28</sup> Ang II also can induce bronchoconstriction, leading to the deterioration of lung function.<sup>29,30</sup> Like ACE inhibitors, ACEI/ARB has significant immunomodulatory effects.<sup>31,32</sup> We believe that ACEI/ARB may alleviate acute lung injury and reduce the deterioration of lung function through the above channels.

Second, angiotensin-converting enzyme II (ACE2), a crucial active biopeptide, is produced through the ACE/ Ang II axis and plays a vital role in preventing lung disease.<sup>33,34</sup> Ferrario was the first to find that ACE inhibitor administration increased ACE2 expression in an animal model.<sup>35</sup> Furthermore, Kriszta reviewed 27 animal studies and found that most of these papers reported increased ACE2 levels after ACEI/ARB treatment.<sup>36</sup> ACE2 can reduce the severity of acute lung injury (ALI) by antagonizing the ACE/Ang II pathway and reducing ALI-induced apoptosis of lung endothelial cells.<sup>37–39</sup> Ye found that ACEI and ARB treatment could attenuate lipopolysaccharide-induced lung injury by increasing ACE2 expression.<sup>40</sup> From both perspectives, we can suggest that the protective effects of ACEI/ARB on the lung are associated with increased ACE2 expression and inhibition of the RAS system by reducing Ang II effects. We plan to test our hypothesis through basic experiments in the next step.

There are some limitations to our study. First, estimating ACEI/ARB use based solely on the use of “admission medications” in discharge records may have biased our analysis. Nevertheless, ACEI/ARB is a very sticky drug, and the likelihood of drug deficiency in this study was minimal. To add credibility to our results, we stratified the patients who continued medication in the hospital. Second, this is a retrospective study, and there may be residual confounding factors.



However, we adjusted for variables associated with ARF risk and balanced the cohort by matching propensity scores. Then, we investigated all-cause mortality because we could not obtain the specific cause of death of the patients. Finally, because pulmonary function tests and annual frequency of exacerbations were not available for this dataset, we could not assess the severity of COPD. However, to our best knowledge, most patients admitted to the ICU with combined ARF were more severe.

## Conclusions

In conclusion, our study found that pre-hospital ACEI/ARB use was associated with reduced mortality in patients with AECOPD combined with ARF. We further found that in-hospital continuation of ACEI/ARB was more protective than patients who discontinued it. Therefore, for patients with AECOPD admitted to the ICU, pre-admission ACEI/ARB use should be continued. Further randomized controlled trials are needed to confirm our results.

## Abbreviations

COPD, Chronic obstructive pulmonary disease; ARF, Acute respiratory failure; ICU, intensive care unit; ACEI, ACE inhibitors; ARB, Angiotensin II receptor blockers; HR, Hazard ratio; SMD, Standardized mean difference; CAD, Coronary artery disease; CHF, Congestive heart failure; PC, Pulmonary circulation disease; PVD, Peripheral vascular disease; APS III, Acute Physiology Score III; OASIS, Oxford acute severity of illness score; qSOFA, quick sequential organ failure assessment score; SIRS, systemic inflammatory response syndrome; LABA, Long-acting  $\beta_2$  agonists; LAMA, long-acting muscarinic antagonist; ARDS, Acute respiratory distress syndrome; ACE, Angiotensin-converting enzyme; ACE2, Angiotensin-converting enzyme II; ALI, Acute lung injury.

## Data Sharing Statement

Data in the article can be obtained from the MIMIC-III database (<https://mimic.physionet.org/>).

## Ethics Approval and Consent to Participate

The project was approved by the institutional review boards of the Massachusetts Institute of Technology and Beth Israel Deaconess Medical Center and was granted a waiver of informed consent. As all data were de-labeled, the Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine exempted our ethical review with the acceptance number 2022–0007.

## Acknowledgments

Zhishen Ruan and Dan Li are co-first authors for this study.

## Author Contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

## Funding

This work was supported by the Jinan Science and Technology Innovation Development Program (202134065) and Shandong Science and Technology Development Program of Traditional Chinese Medicine (2019-0967).

## Disclosure

The authors declare that they have no competing interests.

## References

- Scala R, Heunks L. Highlights in acute respiratory failure. *Eur Respir Rev Off J Eur Respir Soc*. 2018;27(147):180008. doi:10.1183/16000617.0008-2018
- Khilnani GC, Banga A, Sharma SK. Predictors of mortality of patients with acute respiratory failure secondary to chronic obstructive pulmonary disease admitted to an intensive care unit: a one year study. *BMC Pulm Med*. 2004;4:12. doi:10.1186/1471-2466-4-12
- Mancini GBJ, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. *J Am Coll Cardiol*. 2006;47(12):2554–2560. doi:10.1016/j.jacc.2006.04.039
- Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. *Respir Res*. 2009;10:45. doi:10.1186/1465-9921-10-45
- Johnson AEW, Pollard TJ, Shen L, et al. MIMIC-III, a freely accessible critical care database. *Sci Data*. 2016;3:160035. doi:10.1038/sdata.2016.35
- Zhang W, Wang Y, Wang J, Wang S. Association between red blood cell distribution width and long-term mortality in acute respiratory failure patients. *Sci Rep*. 2020;10(1):21185. doi:10.1038/s41598-020-78321-2
- Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *Epidemiol Camb Mass*. 2007;18(6):805–835. doi:10.1097/EDE.0b013e3181577511
- Fortis S, Gao Y, O'Shea AMJ, Beck B, Kaboli P, Vaughan Sarrazin M. hospital variation in non-invasive ventilation use for acute respiratory failure due to COPD exacerbation. *Int J Chron Obstruct Pulmon Dis*. 2021;16:3157–3166. doi:10.2147/COPD.S321053
- Yang Q, Zheng J, Wen D, et al. Association between metformin use on admission and outcomes in intensive care unit patients with acute kidney injury and type 2 diabetes: a retrospective cohort study. *J Crit Care*. 2021;62:206–211. doi:10.1016/j.jcrc.2020.12.007
- Elze MC, Gregson J, Baber U, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular Studies. *J Am Coll Cardiol*. 2017;69(3):345–357. doi:10.1016/j.jacc.2016.10.060
- Bidulka P, Fu EL, Leyrat C, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. *BMC Med*. 2020;18(1):195. doi:10.1186/s12916-020-01659-x
- Tejwani V, Fawzy A, Putcha N, et al. Emphysema progression and lung function decline among angiotensin converting enzyme inhibitors and angiotensin-receptor blockade users in the COPDGene cohort. *Chest*. 2021;160(4):1245–1254. doi:10.1016/j.chest.2021.05.007
- Kim J, Lee JK, Heo EY, Chung HS, Kim DK. The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2016;11:2159–2166. doi:10.2147/COPD.S104097
- Lai CC, Wang YH, Wang CY, Wang HC, Yu CJ, Chen L. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:867–874. doi:10.2147/COPD.S158634
- Petersen H, Sood A, Meek PM, et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. *Chest*. 2014;145(4):695–703. doi:10.1378/chest.13-0799
- Raupach T, Lütjhe L, Kögler H, et al. Local and systemic effects of angiotensin receptor blockade in an emphysema mouse model. *Pulm Pharmacol Ther*. 2011;24(2):215–220. doi:10.1016/j.pupt.2010.12.006
- Angiotensin-converting enzyme inhibition as an adjunct to pulmonary rehabilitation in chronic obstructive pulmonary disease - PubMed. Available from: <https://pubmed.ncbi.nlm.nih.gov/27248440/>. Accessed December 14, 2021.
- Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. *Thorax*. 2003;58(7):629–631. doi:10.1136/thorax.58.7.629
- Kim J, Choi SM, Lee J, et al. Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study. *Korean J Crit Care Med*. 2017;32(2):154–163. doi:10.4266/kjccm.2016.00976
- Jeffery MM, Cummins NW, Dempsey TM, Limper AH, Shah ND, Bellolio F. Association of outpatient ACE inhibitors and angiotensin receptor blockers and outcomes of acute respiratory illness: a retrospective cohort study. *BMJ Open*. 2021;11(3):e044010. doi:10.1136/bmjopen-2020-044010
- Oarhe CI, Dang V, Dang M, et al. Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts. *Pediatr Res*. 2015;77(5):656–662. doi:10.1038/pr.2015.27
- Shrikishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. *Clin Sci Lond Engl*. 2012;123(8):487–498. doi:10.1042/CS20120081
- Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. *Curr Med Chem*. 2011;18(23):3506–3515. doi:10.2174/092986711796642562
- Wang R, Zagariya A, Ibarra-Sunga O, et al. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. *Am J Physiol*. 1999;276(5):L885–889. doi:10.1152/ajplung.1999.276.5.L885
- Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. *EMBO Mol Med*. 2010;2(7):247–257. doi:10.1002/emmm.201000080
- Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J*. 2006;28(1):219–242. doi:10.1183/09031936.06.00053805
- Hanif K, Bid HK, Konwar R. Reinventing the ACE inhibitors: some old and new implications of ACE inhibition. *Hypertens Res off J Jpn Soc Hypertens*. 2010;33(1):11–21. doi:10.1038/hr.2009.184
- Chao J, Donham P, van Rooijen N, Wood JG, Gonzalez NC. Monocyte chemoattractant protein-1 released from alveolar macrophages mediates the systemic inflammation of acute alveolar hypoxia. *Am J Respir Cell Mol Biol*. 2011;45(1):53–61. doi:10.1165/rcmb.2010-0264OC
- Raiden S, Nahmod K, Nahmod V, et al. Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome. *J Pharmacol Exp Ther*. 2002;303(1):45–51. doi:10.1124/jpet.102.037382
- He X, Han B, Mura M, et al. Angiotensin-converting enzyme inhibitor captopril prevents oleic acid-induced severe acute lung injury in rats. *Shock Augusta Ga*. 2007;28(1):106–111. doi:10.1097/SHK.0b013e3180310f3a
- Gullestad L, Aukrust P, Ueland T, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. *J Am Coll Cardiol*. 1999;34(7):2061–2067. doi:10.1016/s0735-1097(99)00495-7

32. Alkharfy KM, Kellum JA, Matzke GR. Unintended immunomodulation: part II. Effects of pharmacological agents on cytokine activity. *Shock Augusta Ga.* 2000;13(5):346–360. doi:10.1097/00024382-200005000-00002
33. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell.* 2020;181(2):271–280.e8. doi:10.1016/j.cell.2020.02.052
34. Lin CI, Tsai CH, Sun YL, et al. Instillation of particulate matter 2.5 induced acute lung injury and attenuated the injury recovery in ACE2 knockout mice. *Int J Biol Sci.* 2018;14(3):253–265. doi:10.7150/ijbs.23489
35. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. *Circulation.* 2005;111(20):2605–2610. doi:10.1161/CIRCULATIONAHA.104.510461
36. Kriszta G, Kriszta Z, Váncsa S, et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on angiotensin-converting enzyme 2 levels: a comprehensive analysis based on animal studies. *Front Pharmacol.* 2021;12:619524. doi:10.3389/fphar.2021.619524
37. Tan WSD, Liao W, Zhou S, Mei D, Wong WSF. Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases. *Curr Opin Pharmacol.* 2018;40:9–17. doi:10.1016/j.coph.2017.12.002
38. Wang L, Li Y, Qin H, Xing D, Su J, Hu Z. Crosstalk between ACE2 and PLGF regulates vascular permeability during acute lung injury. *Am J Transl Res.* 2016;8(2):1246–1252.
39. Khan A, Benthin C, Zeno B, et al. A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome. *Crit Care Lond Engl.* 2017;21(1):234. doi:10.1186/s13054-017-1823-x
40. Ye R, Liu Z. ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway. *Exp Mol Pathol.* 2020;113:104350. doi:10.1016/j.yexmp.2019.104350

## International Journal of Chronic Obstructive Pulmonary Disease

Dovepress

### Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>